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A. Introduction
Ubiquitylation is an enzymatic process of protein modification present in all cells in which a small and highly abundant protein called ubiquitin is physically attached to other proteins. The attachment of ubiquitin to proteins can have several consequences, including activating its function or targeting it for destruction. Ubiquitylation is an important regulatory process in cellular division. However, recent experimental evidence has shown that ubiquitination activity is altered in breast cancers and contributes directly to tumorigenesis.
Understanding how ubiquitination contributes to breast tumorigenesis has been problematic because no experimental tools existed that can identify which proteins are ubiquitylated in cells.
To overcome this limitation, we have developed an innovative experimental assay that enables the identification of ubiquitylated proteins using protein microarrays, containing >8000 human proteins dotted onto glass slides. We have successfully used our assay to identify substrates of purified ubiquitylating enzymes and complex biological mixtures such as breast tumor extracts. The goal of this study is to identify changes in ubiquitylation activity associated with the transformation of normal breast epithelial cells into breast cancers.
B. Body
Establishment of a protein microarray-based ubiquitylation activity profiling assay. Our methodology for profiling ubiquitylation activity in breast tumor specimens is based on protein microarrays, glass microscope slides spotted with >8,000 human recombinant proteins, which serve as substrate for in vitro reactions (Fig. 1) . Ubiquitylation activity is profiled by performing "on-chip" ubiquitylation reactions that include extract from a breast tumor specimen and biotinlabeled ubiquitin. The substrates of ubiquitin conjugation are then detected by incubation of the protein microarrays with fluorescein-labeled strepavidin and visualized using a fluorescence slide reader.
We first focused our efforts on refining our assay system to achieve maximal activity on the protein microarrays. We took this approach since the protein microarrays are expensive Figure 1 . Overview of "on-chip" ubiquitylation reactions using protein microarrays as substrate. Protein microarrays containing >8,300 human recombinant proteins spotted onto glass microscope slides are used as substrates for in vitro ubiquitylation reactions containing biotin-labeled ubiquitin. Substrates are then detected using fluoresceinlabeled strepavidin.
We have successfully employed this methodology to profile the ubiquitin ligase activity of purified ubiquitin ligases and extracts prepared from human and mouse cell lines and primary tumors.
($1,500/each) and believed that the assay should be well-defined before utilizing these materials. In collaboration with Invitrogen Corp., we first created custom protein microarrays which are spotted with ~20 different human recombinant proteins that we showed were ubiquitylated by the extracts of dividing cells. These custom arrays were created by a protein spotting machine at the Invitrogen facility. Using these custom protein microarrays, we established optimal conditions for profiling ubiquitylation activity for the breast tumor extracts (data not shown). Using these optimal conditions, we then performed test reactions on the full protein microarrays (Fig. 2) . We tested extracts prepared from rabbit reticulocytes and S100 fractions of HeLa cells, both known to contain robust ubiquitin ligase activity. The results of these experiments showed that these extracts were capable of ubiquitylating >400 substrates on the protein microarray, including several substrates known to be regulated by the ubiquitin-proteasome system (UPS), as well as many novel substrates (Fig. 2) .
Profiling ubiquitylation activity of breast tumor specimens. We next obtained fresh-frozen breast tumor specimens that were either of low or high pathological stage and grade from the Tumor Bank at the Sidney Kimmel Cancer Center, SKCC). Extracts were generated in ubiquitylation reaction buffer (20 mM Hepes (pH 7.4), 2.5 mM MgCl 2 , 0.5 mM DTT) and protein concentration determined. We then performed ubiquitylation reactions by overlaying tumor extract (50 μg), E1 activating enzyme, ubiquitin, biotin-labeled ubiquitin, and an ATP regeneration system on the full protein microarrays (ProtoArrays, Invitrogen). Reaction mixtures (100 μl) were cover-slipped, and the slides incubated @ 37°C for 1hr in a humidified chamber. Reactions with no ATP regeneration system served as controls. Following a wash in 1M NaCl for 30 min to remove non-covalent interactions, the slides were incubated with fluorescein-labeled strepavidin for 1hr @ 25 °C with shaking. The slides were then analyzed using a Genepix 400B Scanner and fluorescence intensity of each spot quantified with Genepix Figure 2 . Protein microarray-based analysis of ubiquitylation activity in cell and tumor extracts. Ubiquitylation reactions were performed using extract prepared from rabbit reticulocytes (upper middle) and HeLa cells (upper right), whole breast tumor extract (lower right), and purified recombinant SCF Skp2 (lower left). Negative control includes E1, E2, ATP regeneration system, ubiquitin, and biotin-ubiquitin. Positive controls for fluorescence (yellow circles) and examples of ubiquitylated substrates (blue circles) are shown. Pro 6.0 software. The data was then imported in Microsoft Excel and analyzed. Based on control reactions, we chose 500 fluorescence counts as an arbitrary cut off for ubiquitylation activity. We then analyzed the data sets for differences in ubiquitylation between the low and high grade/stage breast cancers. We chose a >2-fold difference in fluorescence intensity at any particular spot as a cut off for a difference between groups. Using these parameters, we found several differences in ubiquitylation activity between low and high grade/stage breast tumors (Table 1) . We then performed a literature search of the differentially ubiquitylated substrates and found that many have defined roles in processes such as DNA repair, cell adhesion, apoptosis, and tumor invasion. Validation of differentially ubiquitylated substrates. We next determined the efficacy of our assay in detecting substrates of ubiquitin conjugation activity, we randomly selected 50 substrates identified on the protein microarrays as ubiquitylated and performed a literature search for evidence for their regulation by ubiquitylation. In 34 cases, the proteins were found to be either regulated by ubiquitin-dependent proteolysis or were known binders of ubiquitin. This represented a nearly 20-fold enrichment over a randomly selected proteins displayed on the protein microarray. We next selected several substrates identified as ubiquitylated on the protein microarrays but not reported in the literature and attempted to validate their ubiquitylation in vivo. We first cloned the cDNAs for the putative ubiquitylated substrates (obtained as Image clones from Open Biosystems) into the expression vector pFlag-CMV2 (Sigma). The substrate expression plasmids were then co-transfected with a HA-ubiquitin expression plasmid into HEK293T cells. After 48 hrs, the cells were incubated in media containing 10 μM of proteasome inhibitor MG132 for 4-6 hrs to stabilize ubiquitylated intermediates. The cells were then lysed in 1% SDS to dissociate protein complexes (denaturing immunopreciptation), the buffer reconstituted to 1x RIPA buffer and extracts immunoprecipitated with anti-Flag antibodies (Sigma). The immunoprecipitates were then separated on SDS-PAGE gels and blotted to nitrocellulose membranes. The membranes were then probed with anti-HA antibodies (Covance) to detect ubiquitylated species. An example of this analysis is shown in Fig. 3 . In all cases tested (4/4), the substrate was found to be a target of modification activity in vivo. (See Appendix for submitted manuscript) 
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E. Conclusions
We have found that key changes in ubiquitylation activity occur as breast tumors progress to advanced disease. The substrates of this activity include several proteins involved in key processes such as DNA repair, cell adhesion, apoptosis, and tumor invasion. The nature of these substrates together with our validation experiments adds confidence that this in vitro assay is faithfully identifying substrates of ubiquitylation activity in vivo. This assay could be applied to other significant problems in breast cancer, such as identify post-translational activity associated with breast cancer metastasis, the chemotherapeutic response, or associated with specific properties of the breast cancer. To overcome these technical limitations, we explored the possibility of using protein microarrays as a platform to profile PTM activity. To date, the analysis of PTMs using protein microarrays has been limited to the phospho-proteome and profiling substrates of purified yeast enzymes (3) (4) (5) . Phosphorylation is a 'simple' PTM compared to the complex enzymatic cascades required for many other modifications such as the conjugation of ubiquitin and ubiquitin-like (Ubl) proteins (e.g. SUMO1 and NEDD8). These modifications are mediated by multi-step enzymatic reactions involving an activating (E1), conjugating (E2), and ligase (E3) enzyme, that selectively transfers the PTM to substrates (1).
G. References
Experimental procedures
Extract Preparation. Cell (HeLa, mouse and human fibroblasts) and tumor (human breast) specimens were suspended in 20 mM Hepes (pH 7.4), 2.5 mM MgCl 2 , 0.5 mM DTT, 5 mM NaF, 1 mM sodium orthovanadate, 1 mM PMSF, 2 μg/ml aprotinin, 1 μg/ml pepsatin, and 1 μg/ml leupeptin, and the cells disrupted by brief sonication. The extracts were clarified by centrifugation for 15 min at 14,000 x g and then snap-frozen in liquid nitrogen until use. Rabbit reticulocyte lysate and HeLa S-100 fractions were purchased from Boston Biochem.
Recombinant Proteins. Human SCF Skp2 complexes were produced in Sf9 cells as described previously (6) . Recombinant Cks1 was produced in bacteria and purified as described (7) . Cyclin A-Cdk2 complexes were purchased from Invitrogen.
Antibodies. Antibodies used in substrate detection on protein microarrays included:
anti-ubiquitin (Biomol, PW8805); anti-SUMO1 (Zymed, 33-2400); anti-NEDD8 (Zymed, 
Results
A schematic of our methodology is shown in Figure 1a . Reactions are performed 'onchip' by overlaying the protein microarrays with a purified conjugation enzyme or extract prepared from a biological specimen (e.g. cell or pathological specimen) and any required factors. The protein microarrays are spotted with ~8,000 different human recombinant proteins in duplicate which serve as substrates for PTM conjugation. The substrates of PTMs are subsequently "tagged" by conjugation of a labeled-modifier (e.g.
biotin-labeled) present in the reaction mixture. Following a stringent wash to remove non-covalent interactions, the conjugated substrates are then detected using 'binders' labeled with fluorescent dye (e.g. antibodies or strepavidin) and the fluorescent signals quantified using a standard slide reader.
As proof of principle, we first sought to determine whether complex PTMs could be profiled using protein microarrays as a platform. Using ubiquitylation as a model system, we profiled substrates of the ubiquitin ligase SCF Skp2 , which has a well-defined role in human tumorigenesis (5) . SCF Skp2 is known to ubiquitylate several substrates including the cyclin dependent kinase inhibitor p27 Kip1 (6, 8) . This reaction is molecularly complex and requires: 1) substrate phosphorylation; 2) association of the substrate with cyclin A-Cdk2 complexes; and 3) the co-factor Cks1. We performed ubiquitylation reactions that included recombinant human SCF Skp2 , E1 and E2 enzymes, ATP regeneration system, ubiquitin, and biotin-labeled ubiquitin. The results of these experiments showed that p27 Kip1 could be efficiently ubiquitylated on the protein microarray by SCF Skp2 , and conjugation activity was only present when all the required components were added to the reaction (Fig. 1b) . In addition to p27 Kip1 , several novel substrates of SCF Skp2 were also identified (Fig. 1b) .
We next tried various perturbations of the ubiquitylation reaction to determine the optimal assay conditions. We evaluated different slide surface chemistries, reaction buffers, assay conditions, and detection methods. PATH slides (glass slides coated with nitrocellulose) proved to be superior to epoxy or hydragel slides in reducing background (data not shown). The addition of 0.1% Tween-20 to both the reaction and wash buffers also significantly limited background and had little effect on PTM conjugation activity. Furthermore, the addition of inhibitors of de-conjugating enzymes (e.g. ubiquitin-aldehyde) was found to increase PTM conjugation activity (data not shown).
Using optimized conditions, we next sought to determine whether this methodology could be used to profile the PTM activity of complex biological mixtures, such as cellular extracts or pathological specimens. We first tested rabbit reticulocyte lysates and S-100 fractions from human HeLa cells, both known to contain robust ubiquitylation activity. These extracts were found to efficiently ubiquitylate many substrates on the protein microarrays (reticulocytes-249; S-100 fraction-119 on the protein microarrays (Fig. 1c, Table 1 ). Summarized in Table 2 are 66 substrates of ubiquitylation activity detected with either rabbit reticulocyte lysate or HeLa S-100 fractions. Several of these substrates were previously shown to either bind ubiquitin (e.g. LIVIN (9), RNF4 (10), ZNF364 (11)), contain ubiquitin binding domains (e.g. CUED1C (12), RAD23A (13)), or are known substrates of ubiquitylation activity (e.g. (16)), lending strong support that this methodology can detect true substrates of ubiquitin conjugation activity. Similarly, whole-cell extracts prepared from various cultured cell lines of both human and mouse origin were also found to efficiently ubiquitylate many (~120) substrates on the protein microarrays (Table 1) . Approximately half of these substrates were found to be consistently ubiquitylated by all the cellular extracts profiled. Collectively, these results demonstrate that this methodology could be used to profile the PTM activity of complex biological specimens of various species origin. Of note, the frequency of ubiquitylated substrates detected on the protein microarrays compares favorably to several proteome-wide analyses of ubiquitylation using mass spectrometry as a platform (17, 18) .
FLT1 (14), JAK2 (15), INSR
A clinically relevant application of this methodology is comparative profiling, wherein disease-associated changes in PTM activity are compared, for example, in normal versus diseased state tissues or during disease progression. To this end, we next profiled the ubiquitylation activity of extracts prepared from human pathological breast tumor specimens that had been kept frozen at -80°C for >10 years. Remarkably, these extracts were found to contain robust ubiquitin-conjugation activity (Table 1) ; comparable to that observed for cellular fractions or whole-cell extracts prepared from cultured cells. Next, we pooled extracts from 5 low-grade and 5 high-grade tumors and applied to the protein microarrays. The results of this analysis showed that differences in ubiquitin conjugation activity occurred as tumors progressed to more advanced stages (Table 3) . Interestingly, several of the differentially modified substrates were found to have defined roles in processes that are central to tumor progression (e.g. growth control, DNA repair, angiogenesis).
We next determined whether this methodology could be easily adapted to other complex PTMs, such as SUMO1 (small ubiquitin-like modifier 1) and NEDD8 (neural precursor cell expressed and developmentally down-regulated 8). SUMO1 and NEDD8
are conjugated to substrates in complex multi-step enzymatic cascades similar to but distinct from ubiquitylation (19) . Reaction conditions used were similar to those used for ubiquitin (described above) except for the substitution of the relevant reaction buffer, E1
enzyme, aldehyde derivative, and biotin-labeled modifier (see Methods). The results of these experiments showed that HeLa cell extracts were capable of conjugating SUMO1
and NEDD8 to many substrates on the protein microarrays ( Table 2 ). Of the SUMOylated substrates identified, HIPK3 (20) and RNF4 (10) were previously shown to bind SUMO1, and the majority of the remainder of substrates contained consensus
SUMO targeting sequences (yKxE/D) (21). Although few substrates of NEDDylation
have been identified (22) (23) (24) , our screen did detect one putative NEDD8 target,
LGALS3, that was previously identified using an alternative proteomic approach (24) .
We next explored whether multiple PTM activities could be simultaneously analyzed on a single protein microarray. For these multiplex experiments, antibodies specific for ubiquitin, SUMO1, NEDD8, and phosphorylated amino acids were labeled with different fluorescent dyes of non-overlapping excitation and emission wavelengths (see Methods). The protein microarrays were first incubated with HeLa cell extracts supplemented with an ATP regenerating system, the various E1 enzymes, aldehydes, and modifiers, and subsequently probed with a mixture of the four PTM detection antibodies. The results of these experiments showed that multiple PTM activities could be simultaneously profiled on the same protein microarray, with some substrates conjugated to multiple modifiers (Fig. 1d) .
To determine the efficacy of this methodology in profiling PTM activity, we selected several PTM substrates that were identified on the protein microarrays but had not been previously reported in the literature and determined whether they were indeed modified in vivo. HEK293T cells were transfected with plasmids that express a taggedmodifier, the putative substrates then immunoprecipitated from the extracts, and PTM conjugation determined by Western blot analysis. YY1, a regulator of the ubiquitin ligase MDM2 that controls the ubiquitin-dependent proteolysis of p53 (25) , was found to be poly-ubiquitylated in HEK293T cells (Fig. 2a) . Additionally, insulin-like growth factor 1 (IGF-1R), a receptor tyrosine kinase that mediates IGF1 signaling (25) , was found to be conjugated to SUMO1 in vivo (Fig. 2b) . Furthermore, p21 Cip1 -activated kinase 3 (PAK3), which is associated with non-syndromic mental retardation in humans (26) , and MUSK, a receptor tyrosine kinase that plays a role in neuromuscular junction organization (27) , were both found to be conjugated to NEDD8 (Fig. 2c) . These results confirm that the PTM activity detected on the protein microarrays was indeed present in vivo.
Discussion
Currently used techniques for profiling PTM activity on a proteome-wide scale have included two-hybrid and high-copy suppressor screens in yeast, and mass spectrometry (24, (28) (29) (30) . However, several limitations exist with these techniques. For example, mass spectrometry-based analyses of PTMs is often complicated by: 1) low substrate abundance, a characteristic of many ubiquitylated proteins, and/or a sub-stoichiometric level of the PTM; 2) the labile nature of many PTMs, making their preservation through biochemical purification, separation techniques, fragmentation, and analysis problematic, especially if native conditions are required leaving substrates vulnerable to de-conjugating enzymes; 3) the adverse effects of certain PTMs on proteases, ionization, and detection efficiency; and 4) multi-site or multi-species modifications, which could make data interpretation problematic.
Our methodology overcomes many of these limitations and provides several distinct advantages. Since the assay measures the intrinsic enzymatic activity of a specimen, it is less sensitive to substrate concentration and sub-stoichiometric modifications are easily detected. The reactions can be performed using crude extracts, eliminating elaborate purification protocols that may promote PTM deconjugation. The methodology can also be easily adapted to the analysis of other PTMs, and multiplexing PTM analyses on the same protein microarray is possible and interpretation of data is not overly complicated. Additionally, the assay can be 
